VALIDATION PUBLICATIONS & ABSTRACTS
Validation Data
Evidence / Validation
FOCUS Trial: Validation of MammaPrint for โฅ 70yrs w/ UltraLow risk of distant recurrence
J Geriatr Oncol. 2022 Nov;13(8):1172-1177 Authors: Noordhoek et al.
Read MoreEquivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests
Publication: ESMO BREAST CANCER CONGRESS 2022 Authors Esther Schuler(1), Sahra Uygun(2), Lorenza Mittempergher(3), Darina Pronin(3), Sammy Mee(2), Simon Bao(2), Tyson Cavness(2), Anke Witteveen(3), and Annuska Glas(3) 1. Zotz|Klimas, MVZ Dรผsseldorf-Centrum GbR, Germany 2. Agendia Inc., Irvine, CA 3. Agendia NV., Amsterdam, Netherlands Background The MammaPrintยฎ 70-gene signature (70GS) risk Read More
Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens
Publication: St Gallen ย Authors: M. Kleijn, J. McKelley, J. Wei, B. Hoxeng, A. Menicucci, S. Wang, T. van Dalen, H. Horlings, W. Audeh Background: Pre-operative/neoadjuvant treatment utilization in early-stage breast cancer has been increasing, particularly during the COVID-19 pandemic. ESMO and ASCO guidelines note that genomic testing on Read More
Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens
PUBLICATION: SABCS 2020 AUTHORS: Joseph McKelley, Jennifer Wei, Brian Hoxeng, Andrea Menicucci, Erin Yoder, Shiyu Wang, William Audeh Background: Pre-operative/neoadjuvant treatment utilization in early-stage breast cancer has been increasing, particularly during the COVID-19 pandemic. With goals of minimizing potential exposure to SARS-COV-2, as well as resource rationing, physicians are urged Read More
ESMO 2020 – Hallmarks of Cancer
PUBLICATION: ESMO 2020 AUTHORS: Josien C. Haan, Rajith Bhaskaran, Lorenza Mittempergher, Ersan Lujinovic, William Audeh, Frederique Penault-Llorca and Annuska M. Glas Background: MammaPrintยฎ (MP) is a 70-gene based assay that stratifies early-stage breast cancer (EBC) patients into low and high-risk of relapse. BluePrintยฎ (BP) is an 80-gene based assay that Read More
Performance Characteristics of the BluePrintยฎ Breast Cancer Diagnostic Test
PUBLICATION: Translational Oncology Volume 13, Issue 4, April 2020, 100756 AUTHORS: Lorenza Mittempergher, Leonie JMJ Delahaye, Anke T Witteveen, Mireille HJ Snel, Sammy Mee, Bob Y Chan, Christa Dreezen, Naomi Besseling, Ernest JT Luiten, Annuska M Glas SUMMARY: The analytical performance of a multi-gene diagnostic signature depends on many parameters, Read More
Performance Characteristics of the BluePrintยฎ Breast Cancer Diagnostic Test
Transl Oncol. 2020 Apr; 13(4): 100756 Authors: Lorenza Mittempergher, et al.
Read More